These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31616168)

  • 1. Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting.
    Hodgson RE
    Clinicoecon Outcomes Res; 2019; 11():517-524. PubMed ID: 31616168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
    Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
    Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.
    Wang D; Schneider-Thoma J; Siafis S; Burschinski A; Dong S; Wu H; Zhu Y; Davis JM; Priller J; Leucht S
    Schizophr Bull; 2024 Jan; 50(1):132-144. PubMed ID: 37350486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
    Okada Y; Inada K; Akazawa M
    Schizophr Res; 2023 Feb; 252():300-308. PubMed ID: 36706475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
    Boyer L; Falissard B; Nuss P; Collin C; Duret S; Rabbani M; De Chefdebien I; Tonelli I; Llorca PM; Fond G
    Mol Psychiatry; 2023 Sep; 28(9):3709-3716. PubMed ID: 37479781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.
    Bartoli F; Cavaleri D; Callovini T; Riboldi I; Crocamo C; D'Agostino A; Martinotti G; Bertolini F; Ostuzzi G; Barbui C; Carrà G;
    Psychiatry Res; 2022 Mar; 309():114405. PubMed ID: 35093701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
    Miyamoto S; Wolfgang Fleischhacker W
    Curr Treat Options Psychiatry; 2017; 4(2):117-126. PubMed ID: 28580230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
    Kyziridis TC
    Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
    Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
    Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
    Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
    Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting.
    Di Lorenzo R; Ferri P; Cameli M; Rovesti S; Piemonte C
    Neuropsychiatr Dis Treat; 2019; 15():183-198. PubMed ID: 30662264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
    Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
    Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
    Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
    Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations.
    Liu Y; Patterson ME; Sahil S; Stoner SC
    Front Pharmacol; 2023; 14():1140969. PubMed ID: 37284307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.